BNF 83 (British National Formulary) March 2022

Product Information

Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure [MHRA/CHM advice] (see advice in Aromatic inhalations, cough preparations and systemic nasal decongestants).

BNF83 (British National Formulary)

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. The new edition (BNF 83) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines. Table of Contents: This edition of BNF continues to broadly follow the high-level structure of previous editions of BNF. Preliminary material, including information on how to use the BNF, significant changes to the content in each edition, and guidance on various prescribing issues (eg, prescription writing, use of intravenous medications, particular considerations for special patient populations). Chapters, which contain drug monographs that describe the uses, dosages, safety issues, and other considerations involved in drug use; drug class monographs; and treatment summaries, which include guidance on medication selection. Treatment monographs and summaries are divided into chapters based on specific aspects of medical care, such as Chapter 5, Infections, or Chapter 16, Emergency Treatment of Poisoning; or drug use related to a particular body system, such as Chapter 2, Cardiovascular. Azithromycin [update to dosing for uncomplicated non-gonococcal urethritis in children aged 12 to 17 years old]. The new edition (BNF 83) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines. Vaccination, general principles: updated guidance on vaccination during pregnancy and breast-feeding.

Vaccines update: restructure of Influenza vaccine monograph—creation of monographs for influenza vaccine (live) and influenza vaccine (inactivated).

BNF 83 (British National Formulary) March 2022 (83rd ed.) BNF 83 (British National Formulary) March 2022 (83rd ed.)

This update contains 3 significant changes, 1 dose change, 3 new monographs, and 3 deleted monographs. The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. Vaccines update [classifications changed to Vaccines, live or Vaccines, inactivated and non-replicating]. Selective serotonin re-uptake inhibitors: breast-feeding advice for all drugs in class and individual drug monographs updated (see examples in fluoxetine and sertraline).Clarithromycin [update to include dosing for prevention of invasive group A streptococcal infection in children from 6 months old and adults]. If you’re a UK-based individual undertaking work or training for the NHS, you can register for access to BNF content on MedicinesComplete. As a registered NHS user, you’ll get single user access to BNF and BNF for Children content on MedicinesComplete for 365 days. This update contains 6 significant changes, 1 dose change, 2 new monographs, 1 new preparation, 4 deleted monographs, and 1 deleted preparation.

BNF Publications Online Access British National Formulary | BNF Publications

Vaccines update: restructure of monograph content—creation of two class monographs, Vaccines, general (information common to all vaccines) and Vaccines, live (information relevant to live vaccines only); see examples in yellow fever vaccine or hepatitis A vaccine. Learn how treatment guidance from Palliative Care Formulary can support health professionals to manage cancer-related neuropathic pain. This update contains 14 significant changes, 5 dose changes, 1 new monograph, 4 new preparations, 2 deleted monographs and 1 deleted preparation. Controlled drugs and drug dependence: updated guidance on prescription requirements for Schedule 2 and 3 Controlled Drugs.This update contains 5 significant changes, 2 new monographs, 2 new preparations, 4 deleted monographs and 2 deleted preparations. Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality [MHRA/CHM advice] (advice in abrocitinib, baricitinib, filgotinib, tofacitinib, upadacitinib; see example in tofacitinib). This update contains 7 significant changes, 5 dose changes, 1 new monograph, and 1 deleted preparation. Rabies vaccine [update to pre-exposure immunisation booster dose in patients who may have frequent, unrecognised exposures e.g. bat handlers]. Vaccines update: restructure of Typhoid vaccine monograph—creation of monographs for typhoid vaccine (live) and typhoid vaccine (inactivated).